Boston Scientific Holds To Year-Long Guidance Despite Weak Sales In August
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific attributes lower than expected stent sales in August to Johnson & Johnson/Cordis' increased stent supply capacity rather than the European launch of Medtronic's Endeavor drug-eluting stent
You may also be interested in...
Medtronic Spotlights Endeavor Stent Launch Abroad, ICDs Domestically
Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.